Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV
NCT ID: NCT03937869
Last Updated: 2020-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
40 participants
INTERVENTIONAL
2018-11-28
2020-11-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single dose Solosec (secnidazole) 2g oral
Solosec 2 grams, oral
Secnidazole
One dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Secnidazole
One dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Are willing and able to give written informed assent with a written informed consent from a parent or legal guardian. (Amendment 01- Assent only if State allowed)
3. Are in good general health including as confirmed by a medical history and physical examination, with no known medical or mental health conditions that, in the Investigator's opinion, may interfere with study participation.
4. Willing and able to participate in the study as an outpatient, make required visits to the study center, and comply with all study requirements.
5. Have a negative urine pregnancy test result prior to study treatment initiation. In addition, female patients of childbearing potential must be using an acceptable form of birth control as determined by the Investigator (e.g., oral contraception, implantable, injectable or transdermal hormonal contraception, intrauterine device \[IUD\], double-barrier methods, have a vasectomized partner or abstinence \[if the patient becomes sexually active they must use one of the acceptable methods of birth control\]). Note: NuvaRing® or any other vaginal ring products are not permitted.
6. Have a clinical diagnosis of bacterial vaginosis, defined as having all of the following criteria:
1. Off-white (milky or gray), thin, homogeneous vaginal discharge AND
2. Vaginal pH \> 4.5 AND
3. Presence of Clue cells of ≥ 20% of the total epithelial cells on microscopic examination of the vaginal saline wet mount AND
4. A positive 10% KOH Whiff test.
7. Agree to abstain from vaginal intercourse until after the TOC visit.
8. Agree not to have any vaginal penetration or use of any vaginal products until after the TOC visit (e.g., spermicides, condoms, diaphragms, vibrators, tampons, etc.).
9. Agree not to use vaginal douches or similar products for the duration of the study.
Exclusion Criteria
2. Are menstruating or have vaginal bleeding at the Baseline Visit (Day 1).
3. Are menopausal as determined by the Investigator.
4. Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae or Herpes simplex or human papilloma virus.
5. Have active genital lesions, including active Herpes simplex lesions, or other vaginal or vulvar conditions which could confound the interpretation of the clinical response, as determined by the Investigator (patients with genital warts that are not being treated may be enrolled).
6. Have received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days prior to the Baseline Visit (Day 1).
7. Are using NuvaRing® or any other vaginal ring products.
8. Have consumed any alcohol within 12 hours prior to treatment with study medication.
9. Have a history of drug or alcohol abuse within the past 6 months, as determined by the Investigator.
10. Have participated in any investigational trial within 30 days or six half-lives of the test drug's biologic activity, whichever is longer, before the Baseline Visit (Day 1).
11. Are participating in any investigational, observational or non-interventional study (either currently or during the study).
12. Have had previous exposure to SYM-1219 or participation in other clinical trials of SYM-1219.
13. Have a known allergy to nitroimidazoles (e.g., metronidazole, tinidazole, nimorazole, etc.).
14. Have a history of an abnormal Pap smear which required cervical biopsy or cervical cauterization within 3 months of the Baseline Visit (Day 1).
15. Have any history of cervical carcinoma or other carcinomas of the vagina or vulva.
16. Have any condition that interferes with their ability to understand or comply with the requirements of the study.
12 Years
17 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lupin Research Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 1004 - Investigational Research Center
Long Beach, California, United States
Site 1005 - Investigational Research Center
Hialeah, Florida, United States
Site 1001 - Investigational Research Center
Miami Lakes, Florida, United States
Site 1010 - Investigational Research Center
Sarasota, Florida, United States
Site 1013
Tampa, Florida, United States
Site 1011 - Investigational Research Center
Bardstown, Kentucky, United States
Site 1008 - Investigational Research Center
Saginaw, Michigan, United States
Site 1007 - Investigational Research Center
Memphis, Tennessee, United States
Site 1006 - Investigational Research Center
Frisco, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SYM-1219-401
Identifier Type: -
Identifier Source: org_study_id